Aileron Therapeutics & Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Enters into a Clinical Collaboration to Treat Pediatric Patients with Cancer

 Aileron Therapeutics & Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Enters into a Clinical Collaboration to Treat Pediatric Patients with Cancer

Aileron Therapeutics & Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Enters into a Clinical Collaboration to Treat Pediatric Patients with Cancer

Shots:

  • The agreement involves onset of P-I trial including Pediatric Patients with solid tumors & acute leukemia receiving ALRN-6924 as a monotx & in combination with cytarabine
  • With the above two studies, an additional study will be initiated involving biomarker with the approach to improve response rates
  • ALRN-6924 is a novel dual inhibitor of MDM2/MDMX and is currently being evaluated to treat solid and hematological cancers, including AML, myelodysplastic syndrome (MDS), and peripheral T-cell lymphoma (PTCL)

Click here to read full press release/ article | Ref: Aileron |Image: Ticker Report

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post